We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current XENE market cap is 3.03B. The company's latest EPS is USD -2.3924 and P/E is -16.64.
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -53.67M | -53.06M | -83.47M | -55.84M | -72.31M |
| Net Income | -47.46M | -48.46M | -44.74M | -47.93M | -57.92M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 6.83M | 32.17M | 18.44M | 9.43M | 0 |
| Operating Income | -42.82M | -31.3M | -78.99M | -129.14M | -214.05M |
| Net Income | -41.6M | -28.01M | -77.09M | -124.94M | -182.39M |
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 684.9M | 671.09M | 964.8M | 919.02M | 884.01M |
| Total Liabilities | 38.44M | 34.5M | 36.88M | 31.33M | 39.96M |
| Total Equity | 646.46M | 636.59M | 927.92M | 887.7M | 844.05M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 147.7M | 189.19M | 572.01M | 754.15M | 964.8M |
| Total Liabilities | 55.72M | 17.83M | 21.97M | 32.65M | 36.88M |
| Total Equity | 91.98M | 171.36M | 550.03M | 721.5M | 927.92M |
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -67.63M | -109.86M | -145.33M | -43.18M | -75.86M |
| Investing | 74.52M | 122.56M | -117.17M | -46.2M | 64.52M |
| Financing | N/A | 29.51M | 353.52M | N/A | N/A |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -4.63M | -48.12M | -69.5M | -98.43M | -145.33M |
| Investing | -66.29M | -16.82M | -246.77M | -296M | -117.17M |
| Financing | 27.52M | 85.8M | 447.54M | 278.47M | 353.52M |
| Market Cap | 3.03B |
| Price to Earnings Ratio | -16.64 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 20.41 |
| Price to Book Ratio | 3.27 |
| Dividend Yield | - |
| Shares Outstanding | 76.24M |
| Average Volume (1 week) | 532.05k |
| Average Volume (1 Month) | 400.14k |
| 52 Week Change | 31.83% |
| 52 Week High | 50.99 |
| 52 Week Low | 28.2005 |
| Spread (Intraday) | 35.29 (55.77%) |
| Company Name | Xenon Pharmaceuticals Inc |
| Address |
200 - 3650 gilmore way burnaby, british columbia V5G 4W8 |
| Website | https://www.xenon-pharma.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
